Potential alterations in management following a revised diagnosis to pCP include more frequent follow-up, consideration of revision surgery in the appropriately selected patient, and consideration of BRAF/MEK inhibitor therapy which is currently transforming the treatment paradigm of pCP [5]. This evidence concerns the gene BRAF and pneumocystosis.